CEBPA mutation analysis
CEBPA mutation analysis-13554
The CEBPA (CCAAT/enhancer binding protein alpha) gene encodes a transcription factor important for granulocyte differentiation. CEBPA mutations are found in 6-15% of de novo acute myeloid leukemia (AML) and in 15-18% of AML with normal karyotypes. CEBPA mutations are associated with favorable prognosis in absence of associated cytogenetic abnormalities and FLT3 internal duplication (FLT3-ITD). Germline CEBPA mutations are a cause of nonsyndromic, familial AML.
Immediately following collection, mix sample thoroughly by gently inverting 8 - 10, times to prevent clotting
Lavender (EDTA), 4 mL
Bone marrow
Immediately following collection, mix sample thoroughly by gently inverting 8 - 10, times to prevent clotting
Whole blood
Dk green Sodium heparin (Na hep), no gel
Bone marrow
Lavender (EDTA), 4mL
Dk green Sodium heparin (Na hep), no gel
Molecular Medicare billing request
Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medicare billing request form to notify us of the need for Allina Health Laboratory to bill insurance.
Ambient (preferred)
Specimen does not meet all of the above criteria for sample type, container, minimum volume, collection and storage.
Unsuitable specimens include but are not limited to:
- frozen whole blood or marrow
- a leaking tube
- clotted blood or marrow
- a grossly hemolyzed specimen or otherwise visibly degraded
- specimen suspected of being contaminated by another specimen
- specimen contains specific foreign material
Polymerase chain reaction (PCR), direct sequencing and capillary electrophoresis
An interpretive report will be included
Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medicare billing request form to notify us of the need for Allina Health Laboratory to bill insurance.